[{"id":"8c77c515-8fd7-47a1-b2a0-d210db442390","acronym":"","url":"https://clinicaltrials.gov/study/NCT00977574","created_at":"2021-01-18T03:48:50.533Z","updated_at":"2024-07-02T16:35:03.140Z","phase":"Phase 2","brief_title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT00977574","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1","pipe":"","alterations":" ","tags":["AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • temsirolimus • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • patupilone (EPO 906)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 03/06/2025","study_completion_date":" 03/06/2025","last_update_posted":"2024-05-17"},{"id":"7e855fb6-2cfa-4b75-acc1-f6614ca4a80d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00877500","created_at":"2021-01-18T03:21:15.288Z","updated_at":"2024-07-02T16:35:08.042Z","phase":"Phase 2","brief_title":"Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy","source_id_and_acronym":"NCT00877500","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ixempra (ixabepilone) • patupilone (EPO 906)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 03/30/2009","start_date":" 03/30/2009","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-23"},{"id":"73ded696-b188-40bd-9d00-ba4f1710bd92","acronym":"CALGB 40502","url":"https://clinicaltrials.gov/study/NCT00785291","created_at":"2021-01-18T02:58:05.514Z","updated_at":"2024-07-02T16:36:02.771Z","phase":"Phase 3","brief_title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","source_id_and_acronym":"NCT00785291 - CALGB 40502","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 799","initiation":"Initiation: 10/13/2008","start_date":" 10/13/2008","primary_txt":" Primary completion: 12/31/2013","primary_completion_date":" 12/31/2013","study_txt":" Completion: 06/15/2017","study_completion_date":" 06/15/2017","last_update_posted":"2022-10-10"},{"id":"6e07b65b-42ca-46be-9269-31596eebf4c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01084057","created_at":"2021-01-18T04:16:30.319Z","updated_at":"2024-07-02T16:36:53.936Z","phase":"Phase 1","brief_title":"Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01084057","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat) • Ixempra (ixabepilone) • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 05/17/2010","start_date":" 05/17/2010","primary_txt":" Primary completion: 11/12/2012","primary_completion_date":" 11/12/2012","study_txt":" Completion: 09/27/2019","study_completion_date":" 09/27/2019","last_update_posted":"2019-11-05"},{"id":"ea2bb81e-0ec6-4ade-9cd8-bb36975d63db","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005807","created_at":"2021-01-17T23:51:21.455Z","updated_at":"2024-07-02T16:37:06.355Z","phase":"Phase 1","brief_title":"Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer","source_id_and_acronym":"NCT00005807","lead_sponsor":"Albert Einstein College of Medicine","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ixempra (ixabepilone) • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2000","start_date":" 07/01/2000","primary_txt":" Primary completion: 08/01/2004","primary_completion_date":" 08/01/2004","study_txt":" Completion: 08/01/2004","study_completion_date":" 08/01/2004","last_update_posted":"2018-10-09"},{"id":"a678500a-79fa-4715-8365-d79669ff7307","acronym":"TITAN","url":"https://clinicaltrials.gov/study/NCT00789581","created_at":"2021-01-18T02:59:38.958Z","updated_at":"2025-02-25T14:30:24.886Z","phase":"Phase 3","brief_title":"A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer","source_id_and_acronym":"NCT00789581 - TITAN","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Ixempra (ixabepilone) • cyclophosphamide intravenous • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 614","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2017-07-02"},{"id":"c64e4a08-e403-4230-ab36-3d42a457255d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00159484","created_at":"2021-01-18T00:32:30.508Z","updated_at":"2025-02-25T15:47:20.936Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT00159484","lead_sponsor":"University of Southern California","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 expression • VEGFA expression","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral • patupilone (EPO 906)"],"overall_status":"Unknown status","enrollment":" Enrollment 75","initiation":"Initiation: 10/01/2004","start_date":" 10/01/2004","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2017-06-27"},{"id":"2f420ad7-706c-4420-afa4-06938b80cf83","acronym":"","url":"https://clinicaltrials.gov/study/NCT01075100","created_at":"2021-01-18T04:14:09.306Z","updated_at":"2025-02-25T14:31:43.629Z","phase":"Phase 2","brief_title":"Ixabepilone + Carboplatin Metastatic Breast Cancer","source_id_and_acronym":"NCT01075100","lead_sponsor":"US Oncology Research","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Ixempra (ixabepilone) • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 06/01/2013","primary_completion_date":" 06/01/2013","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2016-12-07"},{"id":"aaa379a5-f521-49bd-b248-eb6f907e780f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01349088","created_at":"2021-01-18T05:30:36.786Z","updated_at":"2024-07-02T16:37:28.328Z","phase":"Phase 1/2","brief_title":"Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT01349088","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" HER-2 • PGR • KIT","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • PGR • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Ixempra (ixabepilone) • motesanib (AMG 706) • patupilone (EPO 906)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2016-10-21"}]